PD-1/PD-L1 inhibitors

Current Opinion in Pharmacology

Volumn 23, Issue , 2015, Pages 32-38

  Sunshine, Joel ^a   Taube, Janis M ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BMS 936559; CARBOPLATIN; DACARBAZINE; DURVALUMAB; MPDL 3280A; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; PIDILIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; TUMOR MARKER; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADVERSE OUTCOME; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BREAST CANCER; CLINICAL STUDY; COLITIS; COLORECTAL CANCER; DERMATITIS; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FOOD AND DRUG ADMINISTRATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEPATITIS; HODGKIN DISEASE; HUMAN; HYPOPHYSITIS; KIDNEY CARCINOMA; LOSS OF APPETITE; MELANOMA; METASTATIC MELANOMA; MONOTHERAPY; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; PRURITUS; REVIEW; STOMACH CANCER; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ANIMAL; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; NEOPLASMS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84930630766     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2015.05.011     Document Type: Review

References (51)

1. Y. Agata, A. Kawasaki, H. Nishimura, Y. Ishida, T. Tsubata, H. Yagita, and T. Hongo Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes Int Immunol 8 1996 765 772
2. H. Dong, S.E. Strome, D.R. Salomao, H. Tamura, F. Hirano, D.B. Flies, P.C. Roche, J. Lu, G. Zhu, K. Tamada, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat Med 8 2002 793 800
3. T. Yamazaki, H. Akiba, H. Iwai, H. Matsuda, M. Aoki, Y. Tanno, T. Shin, H. Tsuchiya, D.M. Pardoll, K. Okumura, et al. Expression of programmed death 1 ligands by murine T-cells and APC J Immunol 169 2002 5538 5545
4. J.M. Taube, R.A. Anders, G.D. Young, H. Xu, R. Sharma, T.L. McMiller, S. Chen, A.P. Klein, D.M. Pardoll, S.L. Topalian, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape Sci Transl Med 4 2012 ra37
5. M. Ishida, Y. Iwai, Y. Tanaka, T. Okazaki, G.J. Freeman, N. Minato, and T. Honjo Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues Immunol Lett 84 2002 57 62
6. S.Y. Tseng, M. Otsuji, K. Gorski, X. Huang, J.E. Slansky, S.I. Pai, A. Shalabi, T. Shin, D.M. Pardoll, and H. Tsuchiya B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells J Exp Med 193 2001 839 846
7. K. Ishiwata, N. Watanabe, M. Guo, K. Tomihara, M.J. Brumlik, H. Yagita, D. Pardoll, L. Chen, and T. Shin Costimulator B7-DC attenuates strong Th2 responses induced by Nippostrongylus brasiliensis J Immunol 184 2010 2086 2094
8. J.R. Brahmer, C.G. Drake, I. Wollner, J.D. Powderly, J. Picus, W.H. Sharfman, E. Stankevich, A. Pons, T.M. Salay, T.L. McMiller, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J Clin Oncol 28 2010 3167 3175
9. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, L. Rubinstein, J. Verweij, M. Van Glabbeke, A.T. van Oosterom, M.C. Christian, and S.G. Gwyther New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada J Natl Cancer Inst 92 2000 205 216
10. S.L. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, D.F. McDermott, J.D. Powderly, R.D. Carvajal, J.A. Sosman, M.B. Atkins, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454
11. J.R. Brahmer, S.S. Tykodi, L.Q. Chow, W.J. Hwu, S.L. Topalian, P. Hwu, C.G. Drake, L.H. Camacho, J. Kauh, K. Odunsi, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
12. O. Hamid, C. Robert, A. Daud, F.S. Hodi, W.J. Hwu, R. Kefford, J.D. Wolchok, P. Hersey, R.W. Joseph, J.S. Weber, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N Engl J Med 369 2013 134 144
13. C. Robert, A. Ribas, J.D. Wolchok, F.S. Hodi, O. Hamid, R. Kefford, J.S. Weber, A.M. Joshua, W.J. Hwu, T.C. Gangadhar, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial Lancet 384 2014 1109 1117
14. R. Dummer, A. Daud, I. Puzanov, O. Hamid, D. Schadendorf, C. Robert, J. Schachter, A. Pavlick, R. Gonzalez, F.S. Hodi, et al. A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma J Transl Med 13 2015 2062
15. M.B. Atkins, R.R. Kudchadkar, M. Sznol, D.F. McDermott, M. Lotem, J. Schachter, J.D. Wolchok, W.J. Urba, T. Kuzel, L.M. Schuchter, et al. Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma [abstract] J Clin Oncol (Meeting Abstracts) 32 2014 9001
16. R.S. Herbst, J.C. Soria, M. Kowanetz, G.D. Fine, O. Hamid, M.S. Gordon, J.A. Sosman, D.F. McDermott, J.D. Powderly, S.N. Gettinger, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Nature 515 2014 563 567
17. J.R. Brahmer, L. Horn, L. Gandhi, D.R. Spigel, S.J. Antonia, N.A. Rizvi, J.D. Powderly, R.S. Heist, R.D. Carvajal, D.M. Jackman, et al. Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): survival and clinical activity by subgroup analysis [abstract] J Clin Oncol (Meeting Abstracts) 32 2014 8112
18. S.N. Gettinger, F.A. Shepherd, S.J. Antonia, J.R. Brahmer, L.Q.M. Chow, R.A. Juergens, H. Borghaei, Y. Shen, C. Harbison, S. Alaparthy, et al. First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status [abstract] J Clin Oncol (Meeting Abstracts) 32 2014 8024
19. N.A. Rizvi, E.B. Garon, A. Patnaik, L. Gandhi, N.B. Leighl, A.S. Balmanoukian, J.W. Goldman, J.P. Eder, E. Johnson, G.R. Blumenschein, et al. Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC) [abstract] J Clin Oncol (Meeting Abstracts) 32 2014 8007
20. E.B. Garon, N.B. Leighl, N.A. Rizvi, G.R. Blumenschein, A.S. Balmanoukian, J.P. Eder, J.W. Goldman, R. Hui, J.C. Soria, T.C. Gangadhar, et al. Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC) [abstract] J Clin Oncol (Meeting Abstracts) 32 2014 8020
21. J.R. Brahmer, N.A. Rizvi, J. Lutzky, S. Khleif, A. Blake-Haskins, X. Li, P.B. Robbins, J. Vasselli, R.A. Ibrahim, S. Joseph, et al. Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC [abstract] J Clin Oncol (Meeting Abstracts) 32 2014 8021
22. R.J. Motzer, B.I. Rini, D.F. McDermott, B.G. Redman, T.M. Kuzel, M.R. Harrison, U.N. Vaishampayan, H.A. Drabkin, S. George, T.F. Logan, et al. Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial J Clin Oncol 2014 [Epub ahead of print]
23. T.K. Choueiri, M.N. Fishman, B.J. Escudier, J.J. Kim, H.M. Kluger, W.M. Stadler, L.J. Perez-Garcia, D.G. McNeel, B.D. Curti, M.R. Harrison, et al. Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): biomarker-based results from a randomized clinical trial [abstract] J Clin Oncol (Meeting Abstracts) 32 2014 5012
24. E.R. Plimack, S. Gupta, J. Bellmunt, R. Berger, B. Montgomery, E.J. Gonzalez, J. Pulini, M. Dolled-Filhart, K. Emancipator, K. Pathiraja, et al. Phase 1B study of pembrolizumab (pembro; MK-3475) in patients (pts) with advanced urothelial tract cancer [abstract] Ann Oncol (Meeting Abstracts) 25 2014 LBA23A
25. T. Powles, J.P. Eder, G.D. Fine, F.S. Braiteh, Y. Loriot, C. Cruz, J. Bellmunt, H.A. Burris, D.P. Petrylak, S.L. Teng, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Nature 515 2014 558 562
26. S.M. Ansell, A.M. Lesokhin, I. Borrello, A. Halwani, E.C. Scott, M. Gutierrez, S.J. Schuster, M.M. Millenson, D. Cattry, G.J. Freeman, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma N Engl J Med 372 2015 311 319
27. C.H. Moskowitz, V. Ribrag, J.M. Michot, G. Martinelli, P.L. Zinzani, M. Gutierrez, G. DeMaeyer, A.G. Jacob, K. Giallella, J.W. Anderson, et al. PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after Brentuximab vedotin failure: preliminary results from a phase 1b study (KEYNOTE-013) [abstract] Blood (Meeting Abstracts) 124 2014 290
28. A.M. Lesokhin, S.M. Ansell, P. Armand, E.C. Scott, A. Halwani, M. Gutierrez, M.M. Millenson, A.D. Cohen, S.J. Schuster, D. Lebovic, et al. Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies [abstract] Blood (Meeting Abstracts) 124 2014 291
29. J. Hamanishi, M. Mandai, T. Ikeda, M. Minami, A. Kawaguchi, N. Matsumura, K. Abiko, T. Baba, K. Yamaguchi, A. Ueda, et al. Efficacy and safety of anti-PD-1 antibody (nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer [abstract] J Clin Oncol (Meeting Abstracts) 32 2014 5511
30. Nanda R, Chow L, Dees E, Berger R, Gupta S, Geva R, Pusztai L, Dolled-Filhart M, Emancipator K, Gonzalez EJ, et al. A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. Paper presented at: 2014 San Antonio Breast Cancer Symposium, 2014 December 9-13, San Antonio, TX.
31. Emens L, Braiteh F, Cassier P, DeLord JP, Eder JP, Shen X, Xiao Y, Wang Y, Hedge PS, Chen DS, et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. Paper presented at: 2014 San Antonio Breast Cancer Symposium, 2014 December 9-13, San Antonio, TX.
32. T.Y. Seiwert, B. Burtness, J. Weiss, I. Gluck, J.P. Eder, S.I. Pai, M. Dolled-Filhard, K. Emancipator, K. Pathiraja, C. Gause, et al. A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer [abstract] J Clin Oncol (Meeting Abstracts) 32 2014 6011
33. N.H. Segal, S.J. Antonia, J.R. Brahmer, M. Maio, A. Blake-Haskins, X. Li, J. Vasselli, R.A. Ibrahim, J. Lutzky, S. Khleif, et al. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody [abstract] J Clin Oncol (Meeting Abstracts) 32 2014 3002
34. K. Muro, Y. Bang, V. Shankaran, R. Geva, D.V.T. Catenacci, S. Gupta, J.P. Eder, R. Berger, E.J. Gonzalez, J. Pulini, et al. Phase 1b study of pembrolizumab (pembro; MK-3475) in patients (pts) with advanced gastric cancer [abstract] Ann Oncol (Meeting Abstracts) 25 2014 LBA15A
35. C. Robert, G.V. Long, B. Brady, C. Dutriaux, M. Maio, L. Mortier, J.C. Hassel, P. Rutkowski, C. McNeil, E. Kalinka-Warzocha, et al. Nivolumab in previously untreated melanoma without BRAF mutation N Engl J Med 372 2015 320 330
36. J.S. Weber, S.P. D'Angelo, D. Minor, F.S. Hodi, R. Gutzmer, B. Neyns, C. Hoeller, N.I. Khushalani, W.H. Miller Jr., C.D. Lao, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial Lancet Oncol 2015 pii:S1470-2045(15)70076-8 [Epub ahead of print]
37. T.C. Gangadhar, and R.H. Vonderheide Mitigating the toxic effects of anticancer immunotherapy Nature 11 2014 91 99
38. M. Sznol, and L. Chen Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer - response Clin Cancer Res 19 2013 5542
39. J.M. Taube, A. Klein, J.R. Brahmer, H. Xu, X. Pan, J.H. Kim, L. Chen, D.M. Pardoll, S.L. Topalian, and R.A. Anders Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy Clin Cancer Res 20 2014 5064 5074
40. J.S. Weber, R.R. Kudchadkar, B. Yu, D. Gallenstein, C.E. Horak, H.D. Inzunza, X. Zhao, A.J. Matrinez, G. Gibney, J. Kroeger, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma J Clin Oncol 31 2013 4311 4318
41. J. Grosso, C.E. Horak, D. Inzunza, D.M. Cardona, J.S. Simon, A.K. Gupta, V. Sankar, J.S. Park, G. Kollia, J.M. Taube, et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538) [abstract] J Clin Oncol (Meeting Abstracts) 31 2013 3016
42. R. Kefford, A. Ribas, O. Hamid, C. Robert, A. Daud, J.D. Wolchok, A.M. Joshua, S. Hodi, T.C. Gangadhar, P. Hersey, et al. Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475 [abstract] J Clin Oncol (Meeting Abstracts) 32 2014 3005
43. Gandhi L, Balmanoukian A, Hui R, Hamid O, Rizvi NA, Leigh N, Gubens M, Goldman JW, Lubiniecki GM, Emancipator K, et al. MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC): Antitumor activity and association with tumor PD-L1 expression [abstract CT105]. Paper presented at: American Association for Cancer Research Annual Meeting 2014, 2014 April 5-9, San Diego, CA.
44. E.B. Garon, N.B. Leighl, N.A. Rizvi, G.R. Blumenschein, A.S. Balmanoukian, J.P. Eder, J.W. Goldman, R. Hui, J.C. Soria, T.C. Cangadhar, et al. Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC) [abstract] J Clin Oncol (Meeting Abstracts) 32 2014 8020
45. O. Hamid, J.A. Sosman, D.P. Lawrence, R.J. Sullivan, N. Ibrahim, H.M. Kluger, P.D. Boasberg, K. Flaherty, P. Hwu, M. Balinger, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM) [abstract] J Clin Oncol (Meeting Abstracts) 31 2013 9010
46. E.J. Lipson, J.G. Vincent, M. Loyo, L.T. Kagohara, B.S. Luber, H. Wang, H. Xu, S.K. Nayar, T.S. Wang, D. Sidransky, et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival Cancer Immunol Res 1 2013 54 63
47. R. Karim, E.S. Jordanova, S.J. Piersma, G.G. Kenter, L. Chen, J.M. Boer, C.J. Melief, and S.H. van der Burg Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma Clin Cancer Res 15 2009 6341 6347
48. J.D. Wolchok, H. Kluger, M.K. Callahan, M.A. Postow, N.A. Rizvi, A.M. Lesokhin, N.H. Segal, C.E. Ariyan, R.A. Gordon, K. Reed, et al. Nivolumab plus ipilimumab in advanced melanoma N Engl J Med 369 2013 122 133
49. H.J. Hammers, E.R. Plimack, J.R. Infante, M.S. Ernstoff, B.I. Rini, D.F. McDermott, A.R.A. Razak, S.K. Pal, R.H. Voss, P. Sharma, et al. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC) [abstract] J Clin Oncol (Meeting Abstracts) 32 2014 4504
50. P.C. Tumeh, C.L. Harview, J.H. Yearley, I.P. Shintaku, E.J. Taylor, L. Robert, B. Chmielowski, M. Spasic, G. Henry, V. Ciobanu, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance Nature 515 2014 568 571
51. N.A. Rizvi, M.D. Hellmann, A. Snyder, P. Kvistborg, V. Makarov, J.J. Havel, W. Lee, J. Yuan, P. Wong, T.S. Ho, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer Science 2015 Mar 12 pii:aaa1348 [Epub ahead of print]